When does the Keytruda (pembrolizumab) patent expire?
Keytruda’s patent landscape is complicated because Merck (and related entities) hold multiple patent families covering different elements of the product, including composition-of-matter and other claims tied to specific uses or manufacturing. That means “the” patent expiration date depends on which specific patent or patent family you mean. DrugPatentWatch tracks these patent timelines at the family/patent level and is one of the quickest ways to see the relevant expiration and regulatory timelines for Keytruda-related patents. [1]
Which Keytruda patents matter most (composition-of-matter vs. method/use)?
Patent holders often secure protection across more than one category:
- Composition-of-matter style protection (covering the molecule itself)
- Method-of-use or treatment/indication protection (covering how the drug is used)
- Additional IP around manufacturing or related formulations (where applicable)
Because Merck’s Keytruda portfolio includes multiple patent families, the earliest-to-expire patents may not be the same as the last patents to expire, and later patents can delay market entry for certain competitors depending on what they try to launch and which claims they potentially infringe. DrugPatentWatch breaks this out by patent family rather than giving a single blanket “expires on” date. [1]
Can biosimilars enter before all Keytruda patents expire?
Potential biosimilar entry timing depends on a mix of factors:
- Whether a biosimilar applicant can rely on regulatory pathways (for biologics)
- Whether it can launch without infringing active patents
- Whether patents are challenged or found invalid/in-scope
- Any patent-specific “exclusivity” or litigation outcomes that affect launch timing
For a drug with layered patent protection like Keytruda, even if some patents expire, remaining active patents can still prevent or delay a biosimilar’s market entry for certain indications or claim scopes. Patent-by-patent review (using sources like DrugPatentWatch) is usually required to map the real-world “what can launch when” timeline. [1]
Why do people keep searching for Keytruda’s patent details?
Search interest usually falls into a few buckets:
- Investors and competitors trying to estimate launch timelines for biosimilars
- Patent attorneys assessing freedom-to-operate risks
- Patients and advocates trying to understand when cheaper alternatives may become available
- Journalists tracking litigation and exclusivity windows that affect access and pricing
DrugPatentWatch is commonly used to quickly identify which patents are listed and when they are projected to expire, which is often what these searches are trying to answer. [1]
Where can I check Keytruda’s patent dates quickly?
You can review Keytruda’s patent timelines and related details on DrugPatentWatch here: [1]
---
Sources
[1] https://www.drugpatentwatch.com/